NanoViricides, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended December 31, 2015 (the company’s fiscal second quarter and first half of fiscal 2016). The filing is dated February 9, 2016.
Business context
NanoViricides is a pre-revenue biopharmaceutical company developing antiviral nanomedicines. Its programs remain preclinical; the company has not commercialized products. Management’s highest priorities are topical herpes treatments (HerpeCide) and injectable influenza treatment (FluCide). The company relies on TheraCour Pharma, an entity controlled by a significant stockholder, for licensed technology and development services, and on outside collaborators for biological testing.
Financial results and liquidity
- Revenue: None for the quarter or six-month period. No near-term revenue was anticipated.
- Operating expenses: Second-quarter R&D was $1.153 million, up from $0.917 million; G&A was $0.938 million, up from $0.787 million. Six-month R&D was $2.360 million, up from $1.728 million; G&A was $1.956 million, up from $1.590 million.
- Net loss: Second-quarter loss was $2.775 million ($0.05 per basic and diluted share), versus $1.881 million ($0.03 basic and $0.04 diluted) a year earlier. Six-month loss was $4.082 million ($0.07 per basic and diluted share), versus $1.029 million ($0.02 basic and $0.05 diluted) in the prior-year period.
- Margins: Not meaningful because the company had no revenue.
- Cash flow: Six-month operating cash use was $2.867 million, investing cash use was $0.363 million, and financing cash flow was zero. Cash declined by $3.230 million, from $31.468 million at June 30 to $28.238 million at December 31.
- Liquidity and assets: Current assets were $28.344 million, including $28.238 million in cash; current liabilities were $1.467 million. Total assets were $40.849 million.
- Debt and liabilities: Series B and C debentures had face amounts of $6 million and $5 million, respectively; their combined balance-sheet carrying value, net of discounts, was $7.865 million. Series B matures in February 2017 and Series C in June 2018. Total liabilities were $12.465 million. The company also reported $2.883 million of derivative liabilities.
- Equity: Stockholders’ equity was $28.384 million; accumulated deficit was $58.182 million. Common shares outstanding were 57.823 million at December 31.
Material changes and notable items
- Six-month operating expenses rose about 30% year over year, with management attributing higher R&D costs mainly to payroll, laboratory supplies, and materials, and higher G&A to staffing and the new facilities.
- The six-month net loss increased substantially year over year. A noncash derivative fair-value gain of $1.403 million partly offset current-period losses, but was smaller than the $3.409 million gain in the prior-year period. In the second quarter, derivative remeasurement instead produced an $85,467 expense, versus a $391,216 gain a year earlier.
- The company completed relocation of its laboratory and personnel to Shelton, Connecticut. Six-month capital expenditures were $363,486; the filing also records abandonment of fully depreciated fixtures at its former facility.
- Cash interest payments were $490,000. Related-party debenture holders elected to receive quarterly interest in restricted common shares; the filing reports 205,555 common shares issued for debenture interest during the six months.
- Accounts payable to TheraCour rose to $1.111 million from $316,196 at June 30. The company incurred $2.013 million in six-month R&D costs charged by and paid to TheraCour.
Outlook, risks, and contingencies
- Management estimated existing cash could fund operations through at least December 31, 2017 at the then-current spending rate. It believed available funds could support IND-enabling work and initial Phase I/II trials for at least one candidate, while noting that timing and cost estimates were preliminary and actual needs could be higher.
- Management prioritized HerpeCide and injectable FluCide, citing animal-model results and the potential to advance topical herpes candidates more quickly. These are development plans, not evidence of clinical efficacy or regulatory approval. No formal revenue or earnings guidance was provided.
- Management expected continued losses and stated that additional capital could be needed if costs rise, timelines slip, or the company expands its plans. Failure to obtain funding could delay development. All candidates require further studies and regulatory review, and the company has limited experience conducting human trials.
- The company depends on TheraCour’s licensed technology and services. Loss of access could cause substantial development delays and costs. Debenture conversion, interest-payment, redemption, and warrant terms may also create dilution and financing risks.
- Disclosure controls were deemed ineffective because of a material weakness in accounting for complex, non-routine transactions, including derivatives. Management said remediation steps had been taken but were not yet operating long enough to establish effectiveness.
- The filing reported no pending or threatened legal proceedings to the company’s knowledge. A January 23, 2016 amendment approved increasing authorized Series A preferred shares from 4.0 million to 8.5 million.
Important facts for investors to verify
- Whether cash use remains consistent with management’s stated runway and whether additional financing will be required.
- Progress, timelines, and actual costs for IND submissions and clinical trials of HerpeCide and injectable FluCide.
- The terms, maturity obligations, potential dilution, and related-party nature of the Series B and C debentures and associated derivatives.
- Whether the material weakness in financial reporting has been fully remediated and disclosure controls become effective.
- Reliance on TheraCour, including the growing related-party payable and development-cost arrangements.
- The filing’s reporting date is December 31, 2015; confirm that this fiscal-period description matches the intended “2015 Q2” request.